Bone cancers are characterised by the development of tumour cells in bone sites,
associated with a dysregulation of their environment. In the last two decades, numerous …

The androgen/androgen receptor axis in prostate cancer : Current Opinion in Oncology The
androgen/androgen receptor axis in prostate cancer : Current Opinion in Oncology Log in or …

Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the progression of
multiple cancer types through complex mechanisms that are still not fully understood. In this …

Gene fusions involving ETS (erythroblastosis virus E26 transformation–specific) family
transcription factors are found in~ 50% of prostate cancers and as such can be used as a …

In prostate cancer, multiple metastases from the same patient share similar copy number,
mutational status, erythroblast transformation specific (ETS) rearrangements, and …

Advanced medullary thyroid cancers (MTCs) are now being treated with drugs that inhibit
receptor tyrosine kinases, many of which involved in angiogenesis. Response rates vary …

Abstract Purpose: Serine peptidase inhibitor, Kazal type-1 (SPINK1) overexpression defines
the second most recurrent and aggressive prostate cancer subtype. However, the underlying …

Castration-resistance of prostate cancer is one of the most challenging clinical problems. In
the present study, we have performed proteomics and glycomics using LNCaP model …

OBJECTIVES:: Epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases may
be involved in activation of androgen receptor and progression of prostate cancer. They …

The deregulation of the epidermal growth factor receptor (EGFR) pathway plays a major role
in the pathogenesis of prostate cancer (PCa). However, therapies targeting EGFR have …